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ABSTRACT
OBJECTIVES
To study the impact of blinding on estimated 
treatment effects, and their variation between 
trials; differentiating between blinding of patients, 
healthcare providers, and observers; detection bias 
and performance bias; and types of outcome (the 
MetaBLIND study).
DESIGN
Meta-epidemiological study.
DATA SOURCE
Cochrane Database of Systematic Reviews (2013-14).
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Meta-analyses with both blinded and non-blinded 
trials on any topic.
REVIEW METHODS
Blinding status was retrieved from trial publications 
and authors, and results retrieved automatically 
from the Cochrane Database of Systematic Reviews. 
Bayesian hierarchical models estimated the average 
ratio of odds ratios (ROR), and estimated the increases 
in heterogeneity between trials, for non-blinded trials 
(or of unclear status) versus blinded trials. Secondary 
analyses adjusted for adequacy of concealment of 
allocation, attrition, and trial size, and explored the 
association between outcome subjectivity (high, 
moderate, low) and average bias. An ROR lower than 
1 indicated exaggerated effect estimates in trials 
without blinding.
RESULTS
The study included 142 meta-analyses (1153 trials). 
The ROR for lack of blinding of patients was 0.91 
(95% credible interval 0.61 to 1.34) in 18 meta-
analyses with patient reported outcomes, and 0.98 
(0.69 to 1.39) in 14 meta-analyses with outcomes 
reported by blinded observers. The ROR for lack of 
blinding of healthcare providers was 1.01 (0.84 to 
1.19) in 29 meta-analyses with healthcare provider 
decision outcomes (eg, readmissions), and 0.97 
(0.64 to 1.45) in 13 meta-analyses with outcomes 
reported by blinded patients or observers. The ROR 
for lack of blinding of observers was 1.01 (0.86 to 
1.18) in 46 meta-analyses with subjective observer 
reported outcomes, with no clear impact of degree 
of subjectivity. Information was insufficient to 
determine whether lack of blinding was associated 
with increased heterogeneity between trials. The ROR 
for trials not reported as double blind versus those 
that were double blind was 1.02 (0.90 to 1.13) in 74 
meta-analyses.
CONCLUSION
No evidence was found for an average difference in 
estimated treatment effect between trials with and 
without blinded patients, healthcare providers, or 
outcome assessors. These results could reflect that 
blinding is less important than often believed or meta-
epidemiological study limitations, such as residual 
confounding or imprecision. At this stage, replication 
of this study is suggested and blinding should remain 
a methodological safeguard in trials.
Introduction
A randomised clinical trial is the most reliable method 
for assessing the effect of therapeutic interventions.1 
Results of clinical trials underpin evidence based 
clinical practice and decisions made by regulatory 
agencies, either directly or as part of a meta-analysis. 
However, results of randomised clinical trials might 
be biased2—for example, by systematic differences 
between the care provided to participants or systematic 
differences in the behaviour of participants, in the 
intervention and comparison groups (performance 
bias); or by systematic differences between these 
groups in the way in which outcomes are assessed 
(detection bias). Blinding (sometimes called masking) 
of patients, healthcare providers, and outcome 
assessors is intended to prevent such bias.
Blinding is used in some form in about 60% of 
trials.3 However, blinding of patients and healthcare 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Blinding is an established methodological procedure in randomised clinical trials
Empirical estimates of the expected degree of bias in trials due to lack of 
blinding can help interpret trial results (eg, in a systematic review or clinical 
guideline) and plan future trials
Previous meta-epidemiological studies have reported variable estimates of 
the effect of blinding, with little discussion of who was blinded and the type of 
outcome
WHAT THIS STUDY ADDS
This large meta-epidemiological study of 142 Cochrane meta-analyses found 
no evidence that lack of blinding of patients, healthcare providers, or outcome 
assessors had an impact on effect estimates in randomised clinical trials, on 
average
This finding does not support the importance of blinding and is inconsistent 
with some previous studies; but it is consistent with several other smaller meta-
epidemiological studies
The results indicate that blinding, on average, could be less important than 
previously believed, or could reflect limitations in the meta-epidemiological 
approach, such as confounding and misclassification; replication of the study 
is recommended and, at present, no change to methodological practice is 
suggested
 o
n
 29 January 2020 at University of Bristol Library. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l6802 on 21 January 2020. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.l6802 | BMJ 2020;368:l6802 | the bmj
providers is sometimes not possible owing to the type 
of interventions being tested (eg, psychotherapy). In 
other instances, blinding might not be applied owing 
to logistical challenges. Historically, use of placebo 
control interventions and blinding procedures was 
closely linked to early development of the randomised 
trial. Blinding has been an established methodological 
principle since around 1950.4
Various meta-epidemiological studies have 
investigated the effect of blinding on estimated 
intervention effects.5 6 Such studies collate large 
numbers of meta-analyses of randomised trials, 
compare the results of blinded and non-blinded trials 
within meta-analyses, and then combine estimated 
within-meta-analysis differences across meta-
analyses.6 Estimates of the average impact of blinding 
have shown considerable variation between studies.7 
These studies mostly dealt with several types of bias 
simultaneously, and their analyses had conceptual 
and methodological limitations. Comparison of double 
blind trials with trials that are not double blinded is 
problematic, because the double blind concept is 
ambiguous.8 9 This ambiguity is especially clear in non-
pharmacological trials, and the comparison does not 
enable separation of performance bias and detection 
bias. To date, all meta-epidemiological studies of 
blinding have relied exclusively on information 
provided by trial publications, where inadequate 
reporting of blinding is common. Only one study took 
into account by whom outcomes were reported.10
A more comprehensive analysis of the impact of 
blinding in randomised trials is important. Designers 
of trials have to consider whether spending resources 
on blinding is worthwhile. Users of trial information 
(eg, consumers, researchers conducting systematic 
reviews, and guideline developers) must assess the 
risk of bias due to incomplete blinding.
We conducted a meta-epidemiological study to 
estimate the separate effects of blinding patients, 
healthcare providers, and outcome assessors on the 
results of randomised clinical trials. We also estimated 
the impact of different types of blinding on between-
study heterogeneity.
Methods
Identification of meta-analyses for inclusion
We sought meta-analyses that included at least one 
trial with blinding of patients, healthcare providers, 
or outcome assessors (that is, observers) and at 
least one trial without blinding of the same groups. 
We refer to these as informative meta-analyses. To 
identify these, we screened all 1042 Cochrane reviews 
published or updated between 1 February 2013 and 
18 February 2014 (Cochrane Database of Systematic 
Reviews, issue 2, 2013). We used Cochrane risk of 
bias tool2 assessments to select potentially informative 
meta-analyses suitable for further data extraction. 
Specifically, we examined the first listed meta-analysis 
in the review’s table of contents with an observer 
reported outcome and a difference between trials in the 
risk of bias score for detection bias (high v low or high v 
unclear risk); and with a patient reported or healthcare 
provider decision outcome (outcomes determined 
by clinical decisions—eg, readmissions or need for 
surgical intervention) and a difference between trials 
in the risk of bias score for performance bias.
The screening process identified 395 potentially 
informative meta-analyses. Of these, 226 provided 
information on blinding of outcome assessors and 
169 on blinding of patients or healthcare providers. 
For pragmatic reasons, we selected for further study 
a random subsample of 120 meta-analyses from the 
former set, but retained all of the latter set, giving a 
total of 289 potentially informative meta-analyses (full 
details are in the appendix).
Data retrieval and extraction
Trial publications (and any corresponding protocols/
methods publications) were retrieved for each trial 
in each potentially informative meta-analysis. When 
publications could not readily be retrieved, we 
requested a copy from Cochrane review authors. For 
trials published after 1999 and where the blinding 
status of trial participants was unclear we contacted 
authors by email, asking for information on the 
blinding status of all groups within the trial.
We read the full text of publications in languages 
known to us (English, Danish, French, German, and 
Spanish). For publications in other languages (eg, 
Chinese) we based data extraction on any English 
language abstract, but did not attempt translation of 
the full text.
Data on basic trial characteristics and information 
on blinding status were extracted manually from trial 
publications. Trial results were extracted automatically 
from the Cochrane Database of Systematic Reviews 
through the Archie database interface: number of 
patients in intervention and control groups, for binary 
outcomes the number of events, and for measurement 
scale outcomes the means and standard deviations. We 
also automated extraction of the name of the Cochrane 
review group, and review authors’ risk of bias 
assessments for the domains “allocation concealment” 
and “incomplete outcome data.”
Assessment of blinding status
We assessed the blinding status of patients, healthcare 
providers, and outcome assessors using a modified 
algorithm derived from that of Akl and colleagues11 
(full details are given in the appendix). The algorithm 
entailed contacting trial authors (for trials published 
after 1999) when there was insufficient information 
on blinding in the trial publications. We defined 
blinding as a lack of awareness by patients, healthcare 
providers, or outcome assessor of the intervention 
status of individual patients throughout the trial.
We coded healthcare providers as blinded if all 
staff groups involved in patient treatment and care 
were described as “blinded” (eg, doctors and nurses, 
or all staff), and as non-blinded if all, or a subgroup, 
were described as “non-blinded” (eg, surgeons). Staff 
responsible for healthcare provider decision outcomes 
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were thus also covered by the blinding status of 
healthcare providers.
We differentiated between definitive information 
on blinding status (definitely yes/definitely no) based 
on explicit description or contact with trial authors, 
and assessments based on other information in 
publications (probably yes/probably no). For instance, 
for drug trials using a placebo control and described as 
“double blind” or “triple blind,” patients, healthcare 
providers, and outcome assessors were all classified 
as blinded (probably yes), unless stated explicitly 
otherwise. For trials with no mention of “placebo,” 
“double dummy,” “double blinding,” “triple blinding,” 
“single blinding,” or similar, all trial groups were 
classified as non-blinded (probably no), unless stated 
explicitly otherwise. Assessment of blinding status 
was made by two observers independently (AP-M, 
DLTL, LJ, MFO, HM, or AH), and any differences were 
resolved by discussion between the two. When we did 
not receive a reply from authors, or where we did not 
attempt contact, the blinding status was recorded as 
unclear.
When making a final determination of whether 
meta-analyses were informative, and for the purposes 
of our analyses, we compared trials that had relevant 
parties recorded as having “definitely no,” “probably 
no,” or “unclear” blinding with those that had relevant 
parties coded as “definitely yes” or “probably yes.” 
After detailed assessment of blinding status, 189 of 
the 289 meta-analyses were classified as informative.
Classifications and exclusions
Classification of interventions as experimental 
and control was based on descriptions in the trial 
publications, except when the review clearly labelled 
the comparator as “placebo,” “control,” “standard 
care,” or “treatment as usual,” in which case we 
followed the labelling used by the review authors and 
classified these interventions as controls. To ensure 
consistent comparisons of estimated bias across meta-
analyses, we excluded those meta-analyses in which 
intervention classifications were unclear.
Outcome measures were classified as observer 
reported, patient reported (via interviewer or directly 
recorded by patients), healthcare provider decision 
outcomes, or mixed (in instances where the outcome 
was a mixture of more than one category—eg, both 
patient and observer reported elements). We excluded 
meta-analyses of trials that did not all have the same 
type of outcome (eg, patient reported) unless there was 
an informative subset of trials with the same type of 
outcome.
Observer reported outcomes were subdivided 
into four outcomes: objective—all cause mortality, 
objective—other than total mortality (eg, automatised 
non-repeatable laboratory tests), subjective—pure 
observation (eg, assessment of radiographs), and 
subjective—interactive (eg, assessment of clinical 
status). Subjective observer reported outcomes were 
scored 1-3 according to the degree of subjectivity (that 
is, the extent to which determination of the outcome 
depended on the judgment of the observer, with 1 
indicating a low degree of subjectivity). The scoring 
of subjectivity was done by two observers (HM and 
MFO) independently and masked to any results of 
trials or meta-analyses, with any differences resolved 
by discussion. Box 1 shows examples of outcomes and 
subjectivity scores.
Meta-analyses were classified according to 
whether the outcome was measured in the trials 
based on an underlying hypothesis of benefit (eg, 
degree of pain measured based on the hypothesis 
that the intervention lowers pain) or of harm (eg, 
frequency of allergic reactions measured based on 
the hypothesis that the intervention could cause an 
increase). Classification of outcomes according to 
clinical area and type of experimental and comparison 
interventions was conducted to facilitate comparisons 
with an earlier meta-epidemiological study.12 We 
further categorised experimental interventions as 
alternative/complementary or conventional medicine, 
to facilitate comparison with a systematic review of 
trials randomising patients to blinded and unblinded 
substudies.13
We excluded trials with binary outcomes, in which 
no or all participants had the outcome event, and 
trials with continuous outcomes, where the required 
information for calculating the standardised mean 
difference was missing. We also excluded trials 
included in more than one meta-analysis with the same 
outcome, if the meta-analyses were to be included in 
the same meta-epidemiological analysis. Such trials 
were removed at random until the trial occurred only 
within one meta-analysis. After removal of individual 
trials, some meta-analyses were no longer informative. 
The final study database contained 142 meta-analyses 
with a total of 1153 trials.
Data analysis
All main analyses were prespecified. In our main 
analyses, which included only meta-analyses with 
outcomes measured based on a hypothesis of benefit, 
we differentiated between types of bias (detection bias 
and performance bias) and category of person blinded 
(patient, healthcare provider, and outcome assessor). 
We performed five main analyses, quantifying the 
average association between estimates of treatment 
effect and lack of blinding:
Box 1: Examples of subjectivity scoring of trial 
outcomes
• Subjectivity score 1 (low degree of subjectivity): heart 
rate, forced expiratory volume in first second (FEV1), 
cotinine saliva dipstick assay
• Subjectivity score 2 (medium degree of subjectivity): 
superficial surgical site infection, recurrence of 
varicose veins, tooth prosthesis failure
• Subjectivity score 3 (high degree of subjectivity): 
change in global measure of cognition, Barthel index 
score (of ability to perform activities of daily living), 
Hamilton depression scale score
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• (Ia) Blinding of patients in trials with patient 
reported outcomes (considering a combination 
of detection bias and performance bias)
• (Ib) Blinding of patients in trials with blinded 
observer reported outcomes (considering 
performance bias)
• (IIa) Blinding of healthcare providers in trials 
with healthcare provider decision outcomes 
(considering a combination of detection bias 
and performance bias)
• (IIb) Blinding of healthcare providers in trials 
with blinded observers or patients assessing 
the outcome (considering performance bias)
• (III) Blinding of outcome assessors (that is, 
observers) in trials with subjective outcomes 
(considering detection bias). 
We did not primarily focus on trials with objective 
outcomes, such as all cause mortality, because we did 
not suspect any marked effect of blinding in such trials. 
We conducted univariable analyses for each contrast in 
blinding status using all informative meta-analyses for 
that characteristic.
Intervention effects for binary outcomes were 
modelled as log odds ratios and coded such that 
an odds ratio of less than 1 indicated a beneficial 
intervention effect. For continuous outcomes, the 
standardised mean difference and corresponding 
standard error were used and coded such that a 
standardised mean difference of less than zero meant a 
beneficial intervention effect.
We quantified differences in intervention effects, 
comparing non-blinded trials with blinded trials of 
each type using ratios of odds ratios: ROR=ORnon-
blinded/ORblinded. Bayesian hierarchical models for meta-
epidemiological research, developed by Welton and 
colleagues, were used to estimate the average bias 
associated with lack of each type of blinding (ROR), the 
average variability in this bias within a meta-analysis 
(quantified by ĸ, the standard deviation increase 
in heterogeneity between trials), and variability in 
average bias between meta-analyses (quantified by φ, 
the standard deviation in mean bias between meta-
analyses).14
The model thus enabled us to explore the average 
degree of bias, and also whether the bias differs (eg, 
in direction) between meta-analyses (that is, the 
importance of blinding might depend on the clinical 
scenario) and between trials (that is, the importance 
of blinding might depend on factors related to the 
singular trial, even within similar clinical scenarios).
The analyses were carried out using Markov 
chain Monte Carlo simulations in WinBUGS version 
1.4.3. Vague prior distributions were assumed for 
all parameters (see appendix for more details). We 
modelled continuous and binary data simultaneously, 
assuming a mixture of normal and binomial likelihoods 
but modelling the underlying bias on the same scale. 
This method required re-expressing standardised 
mean differences as odds ratios.15 To reduce risk of 
spurious findings, we defined a lower threshold of at 
least 10 meta-analyses for conducting an analysis.
To study the impact of subjectivity scores on the 
average difference in intervention effect associated 
with blinding outcome assessors, we extended the 
model of Welton et al14 to incorporate a three level 
categorical covariate (low v moderate v high degree of 
subjectivity) at the meta-analysis level.
In sensitivity analyses, we excluded trials with a 
classification of blinding status as “unclear” from 
the analyses. Secondary analyses were stratified by 
outcome type (eg, objective outcomes and subtypes).
Confounding by other flaws in trial design was 
assessed in multivariable analyses by re-running each 
of the five main analyses with adjustment in the model 
for concealment of the allocation sequence, incomplete 
outcome data (attrition), trial size, and blinding status 
of patients. The blinding status of patients was only 
included in the analysis of outcome assessor blinding 
(III). We adjusted for each of these characteristics in 
separate analyses. We did not include combinations of 
the covariates.
We also conducted post hoc subgroup analyses 
according to type of outcome data (continuous v 
binary) and type of comparator (active control v inactive 
control), calculated the impact of concealment of the 
allocation sequence on estimated treatment effects, 
and repeated the main analyses using an alternative 
label-invariant meta-epidemiological model, proposed 
recently by Rhodes et al.16 This model removes the 
constraint that intervention effects are at least as 
variable among the non-blinded trials as among the 
blinded trials within each meta-analysis, but was not 
available when we wrote our protocol.
Finally, to facilitate comparison of our results 
with previous meta-epidemiological studies we also 
compared trials described by trial authors as “double 
blind” or “triple blind” with those not described in this 
way.
Patient and public involvement
Patients and members of the public were not involved 
in the research because it was designed to answer 
a methodological challenge that was not directly 
dependent on patient priorities, experiences, or 
participant preferences. The methodological expertise 
required to plan the study, analyse the results, and 
write the manuscript was dependent on specialist 
knowledge and we did not try to identify patients or 
members of the public with this training to work with.
Results
The final study database contained 142 meta-analyses 
with a total of 1153 trials. Figure 1 shows the flow 
of data through the study, from screening to final 
dataset. We contacted the trial author for 54 (5%) 
of the 1153 trials in the dataset. In 28 instances the 
authors replied (response rate 52%), and the fraction 
of trials with unclear blinding status was thereby 
reduced from 95/1153 (8%) to 67/1153 (6%). 
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Ia
Effect of blinding
patients in
trials with patient
reported
outcomes
Ib
Effect of blinding
patients in
trials with blinded
observer reported
outcomes
IIa
Effect of blinding
healthcare
providers in trials
with healthcare
provider decision
outcomes
IIb
Effect of blinding
healthcare
providers in trials
with blinded
observers/patients
assessing outcome
III
Effect of blinding
outcome
assessors (that is,
observers) in trials
with subjective
outcomes
21 (155)
18 (132)
3 (23)
All*
Hypothesis of benefit*
Hypothesis of harm*
14 (95)
14 (95)
0
35 (226)
29 (173)
6 (53)
14 (96)
13 (91)
1 (5)
51 (413)
46 (397)
5 (16)
Removed trials
Either no or all participants experienced outcome event (not possible to calculate odds
  ratio)
Missing required information to calculate standardised mean difference
Removed since included with same outcome in two meta-analyses due to be included
  in same meta-epidemiological analysis. Removed at random from one of the meta-
  analyses
28 meta-analyses in which it was not clear which intervention was experimental and
  which was control
5 meta-analyses with inverse variance outcomes (not standardised mean difference)
14 meta-analyses were lost as they were non-informative about the effect of blinding
  patients, care providers, or outcome assessor due to removal of trials
106
2
1
300
57
83
549
Excluded reviews with no informative meta-
analyses based on risk of bias assessments
All Cochrane reviews published or updated between 1 February 2013 and 18 February 2014
1042
Potentially informative meta-analyses
Reviews
395 potentially informative meta-analyses, of which 226 had observer reported outcomes
747
Excluded meta-analyses at random, of 226, 
with observer reported outcomes owing 
to an excess of such meta-analyses
106
Excluded meta-analyses not informative
based on information on blinding in trial
publications/contact with trial authors
100
295
289
Initial MetaBLIND database
Meta-analyses informative based on information in trial publications (1702 trials)
189
MetaBLIND analysis dataset
Meta-analyses (1153 trials)
142
Fig 1 | Study flow diagram. *Meta-analyses contributing with trials that had outcome measures categorised as “mixed” 
(that is, it was not possible to classify them as patient reported, healthcare provider decision, or observer reported 
because they contained elements from more than one of these types) were not counted. Mixed outcome trials did not 
contribute to the main analyses
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Appendix table 1 shows the proportions of trials 
classified as definitely yes and probably yes.
Table 1 shows characteristics of the 142 meta-
analyses and 1153 trials included in the dataset. The 
median year of trial publication was 2003 (interquartile 
range 1996-2008), and the median sample size was 
768 (293-2025) patients for meta-analyses and 106 
(50-270) for trials. Of the 1153 trials included in 
the analysis dataset, 1112 (96%) had a parallel trial 
design and 753 (65%) were drug trials. Full details are 
given in appendix table 1.
Various methodological characteristics were strongly 
associated across trials. For instance, trials in which 
the outcome assessor was blinded were more likely 
to have adequate allocation concealment (odds ratio 
3.0, 95% confidence interval 2.2 to 4.0) and complete 
outcome data (2.0, 1.5 to 2.8). Trials reporting that 
patients were blinded were more likely to report that 
the outcome assessor was blinded (75.0, 38.6 to 
145.8). Full details are shown in appendix tables 2 and 
3. Figure 2 presents results for each of the five main 
analyses (Ia, Ib, IIa, IIb, III). Forest plots of the meta-
analyses are shown in appendix figure 1.
For the effect of blinding patients in trials with patient 
reported outcomes (analysis Ia), 18 informative meta-
analyses with a hypothesis of benefit contained 132 
trials. Patient blinding was assessed as probably yes or 
definitely yes in 33 trials (25%). The average ROR was 
0.91 (95% credible interval 0.61 to 1.34). The average 
standard deviation increase in heterogeneity between 
trials among non-blinded trials was very imprecisely 
estimated and is presented in figure 2 and appendix 
table 4, together with implied 95% predictive intervals 
for the ROR in a single trial, to facilitate interpretation. 
For the effect of blinding patients in trials with 
blinded observer reported outcomes (analysis Ib), 14 
informative meta-analyses with a hypothesis of benefit 
contained 95 trials. Patient blinding was assessed as 
probably yes or definitely yes in 57 (60%) of these. The 
average ROR was 0.98 (95% credible interval 0.69 to 
1.39).
For the effect of blinding healthcare providers in 
trials with healthcare provider decision outcomes 
(analysis IIa), 29 informative meta-analyses with a 
hypothesis of benefit contained 173 trials. Healthcare 
provider blinding was assessed as probably yes or 
definitely yes in 93 of these trials (54%). The average 
ROR was 1.01 (95% credible interval 0.84 to 1.19). For 
the effect of blinding healthcare providers in trials with 
blinded observers or patients assessing the outcome 
(analysis IIb), 13 informative meta-analyses with a 
hypothesis of benefit contained 91 trials. Healthcare 
provider blinding was assessed as probably yes or 
definitely yes in 61 trials (67%). The average ROR was 
0.97 (95% credible interval 0.64 to 1.45).
For the effect of blinding outcome assessors (that is, 
observers) in trials with subjective outcomes (analysis 
III), 46 informative meta-analyses with a hypothesis 
of benefit contained 397 trials. Outcome assessor 
blinding was assessed as probably or definitely yes in 
199 of these trials (50%). The average ROR was 1.01 Ta
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(95% credible interval 0.86 to 1.18). In the additional 
analysis in which we explored the impact of the level 
of subjectivity of the outcome, we estimated average 
RORs of 0.94 (0.71 to 1.21), 1.05 (0.83 to 1.38), and 
1.10 (0.75 to 1.63) for outcomes with low, moderate, 
and high degree of subjectivity, respectively.
For each of the five main analyses, separate 
adjustment for concealment of the allocation sequence, 
attrition, and trial size did not materially change the 
result (table 2). Estimated increases in heterogeneity 
between trials and estimates of variability between 
meta-analyses in average bias also did not change 
substantially, compared with the unadjusted main 
analyses. 
Analyses comparing trials described as “double 
blind” (or “triple blind”) with those not so described, 
or with an unclear status, did not show any effect 
when they included meta-analyses with any type of 
outcome (ROR 0.99, 95% credible interval 0.86 to 
1.09), nor when they included only meta-analyses 
with subjective observer reported outcomes and a 
hypothesis of benefit (1.11, 0.86 to 1.44; table 3). 
Exclusion of trials with an unclear blinding status 
from the unadjusted main analyses did not change 
the results substantially (table 3).
Results of secondary analyses looking separately at 
the effect of blinding patients, healthcare providers, 
or outcome assessors across different types of 
outcomes are shown in appendix table 5. For example, 
an analysis based on observer reported outcomes 
classified as objective also showed little evidence of an 
effect of outcome assessor blinding status (ROR 0.94, 
95% credible interval 0.61 to 1.26; meta-analyses with 
a hypothesis of benefit only).
A pre-planned repetition of the main analyses based 
only on trials scored as definitely yes versus trials scored 
as definitely no proved unfeasible due to insufficient 
numbers of meta-analyses (appendix table 5). A post 
hoc analysis indicated about 10% exaggeration of 
the odds ratio in trials without adequate concealment 
of the allocation sequence (table 3). We report the 
results of other post hoc analyses for type of outcome 
(continuous v binary) and type of comparator (active 
control v inactive control) in table 3.
Results for the five main analyses repeated using the 
alternative, label-invariant, model of Rhodes et al16 are 
presented in appendix table 6. The estimates of ROR and 
of heterogeneity between meta-analyses in bias from 
both models were similar. Results for heterogeneity 
between trials were not directly comparable to those 
for the main model, but indicated a possible increase 
in heterogeneity among blinded trials, although again 
the parameter estimates were very imprecise.
Discussion
We found no evidence of a difference, on average, 
in estimated treatment effects between randomised 
clinical trials with and without blinding of patients, 
between trials with and without blinding of healthcare 
providers, and between trials with and without blinding 
of outcome assessors. In all instances the credible 
intervals were wide, including both considerable 
difference and no difference. The same pattern was 
found when comparing trials that were double blind 
with those that were not. Our findings of an increase in 
heterogeneity between trials are inconclusive, owing to 
a lack of information.
Strengths and challenges of the study
The main strengths and originality of our study were 
that blinding was analysed according to the type of 
person blinded and due consideration given to the type 
of outcome. Analysis in this way allowed a separation 
of the two main types of blinding related bias 
(Ia) Patients - patient reported outcomes (18, 132)
(Ib) Patients - blinded observer reported outcomes (14, 95)
(IIa) Healthcare providers - healthcare provider decision outcomes (29, 173)
(IIb) Healthcare providers - outcomes assessed by blinded observers/patients (13, 91)
(III) Outcome assessor - subjective outcomes (46, 397)
  Low (15, 155)
  Moderate (23, 165)
  High (8, 77)
0.91 (0.61 to 1.34)
0.98 (0.69 to 1.39)
1.01 (0.84 to 1.19)
0.97 (0.64 to 1.45)
1.01 (0.86 to 1.18)
0.94 (0.71 to 1.21)
1.05 (0.83 to 1.38)
1.10 (0.75 to 1.63)
0.6 0.75 1.251 1.5
Trial group (No of contributing
meta-analyses, contributing trials)
Ratio of odds
ratios
(95% credible
interval)
Ratio of odds
ratios
(95% credible
interval)
0.22
0.10
0.06
0.10
0.05
Increase in
standard
deviation
between
trials*
0.20
0.11
0.06
0.13
0.09
Standard
deviation
between
meta-
analyses†
Fig 2 | Estimated ratios of odds ratios and effects on heterogeneity associated with blinding status of patients, healthcare providers, and outcome 
assessors. Unadjusted analyses. *Increase in standard deviation between trials: (Ia) 0.22 (95% credible interval 0.02 to 0.60), (Ib) 0.10 (0.01 to 
0.30), (IIa) 0.06 (0.01 to 0.30), (IIb) 0.10 (0.01 to 0.59), (III) 0.05 (0.01 to 0.22). †Standard deviation between meta-analyses: (Ia) 0.20 (95% credible 
interval 0.01 to 0.74), (Ib) 0.11 (0.01 to 0.55), (IIa) 0.06 (0.01 to 0.26), (IIb) 0.13 (0.01 to 0.82), (III) 0.09 (0.01 to 0.31)
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(performance and detection bias) and enabled a 
comprehensive analysis that was less reliant on the way 
in which authors used the phrase “double blind.” Also, 
we had a low proportion of trials with unclear blinding 
status, partly because we attempted to contact the trial 
authors. We restricted the main analyses to outcomes 
measured, based on a hypothesis of benefit, and 
ensured that interventions considered experimental in 
our analyses were also regarded as experimental in the 
individual trials.
The specificity of the comparisons limited the 
number of trials and meta-analyses that could be 
included in individual analyses, which restricted the 
precision of estimated differences between trials with 
and without the various types of blinding. We planned 
our sample size pragmatically, primarily based on 
results of comparisons within trials.13 17-19 Formal 
power calculations were published after we had 
planned our study.20
Meta-epidemiological studies are observational 
and so estimated effects of trial characteristics could 
be confounded. We adjusted for predefined variables 
such as allocation concealment, attrition, trial size, 
and blinding status of patients. Concurrent adjustment 
for a combination of factors was not feasible, and 
confounding by unknown or unmeasured factors 
could have affected results.
Confounding by other methodological 
characteristics can be expected to exaggerate the 
estimated effect of lack of blinding, rather than cancel 
it. Nevertheless, attenuation of the estimated effect 
of blinding by confounding cannot be ruled out. For 
instance, more pragmatically conducted trials within 
a meta-analysis (those with the broadest inclusion 
criteria and with least control of treatment adherence) 
could be less likely to have used blinding and could 
have resulted in less beneficial treatment effects than 
more explanatory trials. The consequence would be to 
move the estimated ROR towards 1.
Blinding could have less impact in trials comparing 
an experimental intervention with an active comparator 
(that is, not compared with placebo, no treatment, 
or standard care). Type of comparator, however, did 
not seem to affect the analysis of outcome assessor 
blinding, and too few informative meta-analyses 
precluded additional analyses. Possibly, blinding 
could have less impact in trials that aim to determine 
an intention-to-treat effect than in trials aiming to 
determine a per protocol effect. We did not explore 
whether the impact of blinding differed according to 
inferential goal or type of analysis.
Blinding could be lost during the course of a trial,21 
which would tend to attenuate the apparent differences 
between blinded and non-blinded trials. Other factors 
to consider are a possibly larger impact of non-
reporting bias on blinded trials, and misclassification 
(despite our intensive efforts to classify correctly the 
blinding status of patients, healthcare providers, 
and outcome assessors). In general, non-differential 
misclassification would bias our results towards no 
impact of lack of blinding.T
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The generalisability of our results could be 
affected by the sampling strategy inherent in a meta-
epidemiological approach. Thus, inclusion of only 
meta-analyses containing both blinded and non-
blinded trials excludes situations where all trials 
are blinded (as blinding is considered of paramount 
importance) or, conversely, areas where all trials tend 
to be non-blinded. Similarly, review authors might be 
more likely to include both blinded and non-blinded 
trials in a meta-analysis when there is no clear 
difference in effect estimates between the two.
Our estimation of average bias (ROR) was robust 
with regard to choice of statistical model.14 16 The same 
applied to our analyses of heterogeneity in bias between 
meta-analyses. The model restriction embedded in the 
additive model by Welton and colleagues,14 used for 
our main analyses, however, implies that between-
trial heterogeneity among non-blinded trials can 
only increase (or remain unchanged). We reanalysed 
our data with an alternative model not restricted by 
this assumption,16 which was not available when 
we planned our study. The reanalysis indicated a 
possible decrease in heterogeneity among non-blinded 
trials, although estimates were imprecise, and results 
were also consistent with a considerable increase 
in heterogeneity between trials. We interpret this 
result cautiously, to imply that there was insufficient 
information to determine whether lack of blinding 
was associated with increased heterogeneity between 
trials. Few direct comparisons have been published 
Table 3 | Secondary analyses. Data are outcome measure (95% credible interval) unless stated otherwise
No of  
meta-analyses, 
trials
ROR Ф ĸ
Lack of double blinding or unclear double blinding (v double blind)
All outcomes 94, 722 0.99  (0.86 to1.09)
0.07  
(0.01 to 0.29)
0.06  
(0.01 to 0.18)
 Benefit 74, 583 1.02  (0.90 to 1.13)
0.06  
(0.01 to 0.27)
0.07  
(0.01 to 0.19)
 Harms 20, 139 0.64  (0.38 to 1.04)
0.15  
(0.01 to 0.89)
0.13  
(0.01 to 1.23)
Observer reported outcomes: benefit 36, 374 1.04  (0.84 to 1.25)
0.14  
(0.01 to 0.57)
0.08  
(0.01 to 0.23)
Subjectively assessed observer reported outcomes: benefit 27, 221 1.11  (0.86 to 1.44)
0.13  
(0.01 to 0.61)
0.09  
(0.01 to 0.42)
Patient reported outcomes: benefit 13, 53 0.89  (0.57 to 1.40)
0.15  
(0.01 to 0.83)
0.12  
(0.01 to 0.88)
Healthcare provider decision outcomes: benefit 24, 147 0.98  (0.79 to 1.19)
0.07  
(0.01 to 0.31)
0.07  
(0.01 to 0.36)
Repeat of the main analyses excluding trials with unclear blinding status
(Ia) Effect of blinding patients in trials with patient reported outcomes 16, 116 1.10  (0.72 to 1.69)
0.19  
(0.02 to 0.76)
0.23  
(0.02 to 0.61)
(Ib) Effect of blinding patients in trials with blinded observer reported outcomes 14, 94 1.00  (0.70 to 1.44)
0.11  
(0.01 to 0.58)
0.10  
(0.01 to 0.60)
(IIa) Effect of blinding healthcare providers in trials with healthcare provider decision outcomes 28, 160 0.97  (0.77 to 1.18)
0.08  
(0.01 to 0.36)
0.07  
(0.01 to 0.39)
(IIb) Effect of blinding healthcare providers in trials with blinded observers/patients assessing the out-
come 13, 90
0.96  
(0.64 to 1.45)
0.14  
(0.01 to 0.82)
0.10  
(0.01 to 0.68)
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes 43, 365 1.01  (0.85 to 1.20)
0.11  
(0.01 to 0.35)
0.06  
(0.01 to 0.25)
Main analysis by type of outcome
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes: continu-
ous* 14, 108
dSMD 0.02  
(−0.22 to 0.26)
0.07  
(0.01 to 0.37)
0.07  
(0.01 to 0.31)
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes: binary* 32, 289 1.01  (0.85 to 1.20)
0.11  
(0.01 to 0.37)
0.06  
(0.01 to 0.23)
Main analyses by type of control intervention
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes: active 
 control* 12, 61
1.01  
(0.64 to 1.55)
0.12  
(0.01 to 0.70)
0.10  
(0.01 to 0.56)
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes: inactive 
control  
(placebo/no treatment/standard care)*
34, 336 1.01  (0.85 to 1.21)
0.10  
(0.01 to 0.36)
0.06  
(0.01 to 0.23)
Inadequate (or unclear) concealment of the allocation sequence (v adequate)
(Ia) Effect of blinding patients in trials with patient reported outcomes† 13, 116 0.95  (0.68 to 1.29)
0.11  
(0.01 to 0.63)
0.10  
(0.01 to 0.51)
(IIa) Effect of blinding healthcare providers in trials with healthcare provider decision outcomes† 22, 154 0.90  (0.72 to 1.12)
0.09  
(0.01 to 0.35)
0.07  
(0.01 to 0.32)
(III) Effect of blinding outcome assessors (that is, observers) in trials with subjective outcomes† 40, 349 0.88  (0.76 to 1.02)
0.07  
(0.01 to 0.27)
0.08  
(0.01 to 0.30)
ROR=ratio of odds ratios; ĸ=standard deviation increase in heterogeneity between trials; Ф=standard deviation in mean bias between meta-analyses; dSMD=difference in standardised mean 
difference.
*The prespecified minimum of 10 meta-analyses for analysis to be feasible was met only in analysis III. 
†Analyses include meta-analyses from each of the datasets used in the main analyses that were informative for the impact of inadequate (or unclear) concealment of the allocation sequence. The 
numbers of informative meta-analyses in analyses Ib and IIb did not meet the prespecified minimum of 10 meta-analyses for analysis to be feasible.
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between the newly developed label-invariant model16 
and the additive model14 used in our study and in most 
large meta-epidemiological studies.12 22 Analyses of 
the ROBES study database based on the additive model 
indicated an increase in heterogeneity between trials 
among trials with inadequate or unclear concealment 
of allocation, whereas the label-invariant model 
indicated a decrease.16
Other studies
Systematic reviews of meta-epidemiological studies7 23 
identified four studies (comparisons within meta-
analyses) estimating the impact of blinding patients, 
three studies estimating the impact of blinding trial 
personnel, and four studies estimating the impact of 
blinding outcome assessors. In all instances, blinding 
had surprisingly little effect.7 23 Two additional recent 
studies partly confirmed this pattern: an analysis 
of physiotherapy trials24 found little evidence of an 
impact of blinding of patients or of outcome assessors, 
and a study of oral health trials25 found no evidence 
of an impact of blinding of outcome assessors, though 
some evidence of a moderate effect of patient blinding.
By contrast, three systematic reviews of within-trial 
comparisons for 51 trials with both blinded and non-
blinded outcome assessment found that blinding had 
a clear effect.17-19 For example, non-blinded outcome 
assessors of subjective26 outcomes exaggerated odds 
ratios by 36%, on average.17 Similarly, a systematic 
review of 12 trials randomising patients to blinded 
and non-blinded substudies reported a pronounced 
bias due to lack of patient blinding in complementary/
alternative medicine trials with patient reported 
outcomes, exaggerating effect sizes by 0.56 standard 
deviations.13 Such comparisons within trials have 
no major risk of confounding. The trial design is 
rare, however, so to what extent the results could be 
generalised is not clear.
Results of meta-epidemiological studies comparing 
double blind trials with trials without (or unclear) 
double blinding have shown noticeable variation.7 A 
systematic review by Page and colleagues found an 
overall 8% exaggeration of odds ratios in trials without 
double blinding (although confidence intervals 
overlapped no effect),7 and an exaggeration of 23% 
when outcomes were subjective.7 12
Mechanisms and implications
Clarification of the circumstances in which blinding 
is important in trials, and an empirical assessment 
of direction and degree of bias, have important and 
direct implications for the design of future trials, for 
interpretation of trial results, and for instructions on 
how to assess risk of bias when conducting systematic 
reviews. Clarification is also pertinent to the current 
debate on the balance between reliability and relevance 
of unblinded patient reported outcome measures 
(PROMS),27 28 and the relative importance of blinded 
explanatory trials versus unblinded pragmatic trials.29
Convincing theoretical reasons lead us to expect 
both detection and performance bias in non-blinded 
trials. Experimental psychology backs the notion 
that expectations and interest tend to shape human 
evaluations.30 31 Comparisons within trials13 17-19 
provide strong evidence that in specific settings lack of 
blinding in trials causes considerable bias. Exactly what 
characterises these settings is unclear, however. We 
suggest that replication of our study would be valuable, as 
would updates of the systematic reviews of comparisons 
within trials, and exploration of the conditions under 
which blinding is more, or less, important.
Meta-epidemiological studies are often used to assess 
empirically dimensions of bias in randomised trials, but 
they could themselves be biased. For example, meta-
epidemiological studies of allocation concealment 
have disclosed an unexpected dependence of impact on 
type of outcome.12 Theoretically, impact of allocation 
concealment should not depend on the subjectivity 
of outcomes.7 32 We suggest careful consideration of 
the risk of confounding and of bias, such as bias due 
to misclassification of methodological characteristics 
or due to erroneous identification of treatments as 
experimental and control, in meta-epidemiological 
studies.33
Blinding has been considered an essential 
methodological precaution in trials for decades. 
We did not expect to find that our study does not 
firmly underpin standard methodological practice. 
Further, our results are coherent with other meta-
epidemiological studies that have reported similar 
results. The implication seems to be that either blinding 
is less important (on average) than often believed, that 
the meta-epidemiological approach is less reliable, or 
that our findings can, to some extent, be explained by 
lack of precision. At present, we suggest that assessors 
of the risk of bias in trials included in a systematic 
review continue to deal with the implications of lack of 
blinding for risk of bias, as is done in version 2 of the 
Cochrane risk of bias tool.34
In conclusion, we found no evidence of a difference, 
on average, in estimated treatment effect between 
randomised clinical trials with blinded and non-
blinded patients, between trials with blinded and 
non-blinded healthcare providers, and between trials 
with blinded and non-blinded outcome assessors. The 
apparent lack of a major average effect of blinding on 
estimated treatment effects is surprising to us and is at 
odds with methodological standard practices. We are 
unclear to what extent our results show that blinding 
is less important than previously believed, show the 
limitations of the meta-epidemiological approach (eg, 
residual confounding), or show a lack of precision 
in the comparisons made. Until our study has been 
replicated, and we have a clearer understanding of 
which types of trials are susceptible to bias associated 
with lack of blinding, we suggest that blinding remains 
an important methodological safeguard in trials in 
which it is feasible.
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